Quarterly ResultAug 6, 2026, 08:08 AM
Prime Medicine Advances 3 Programs, PM577a Cleared for Phase 1/2, Q2 Net Loss $42.1M
AI Summary
Prime Medicine reported a net loss of $42.1 million for Q2 2026, an improvement from $52.6 million in Q2 2025, with R&D and G&A expenses decreasing. The company announced significant clinical progress, including IND and CTA clearances for PM577a in Wilson disease, establishing a global Phase 1/2 program. They also secured rights to PM647 in Alpha-1 Antitrypsin Deficiency following a favorable arbitration and received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for PM359, with a BLA submission planned for 1H 2027. Prime Medicine ended the quarter with $108.8 million in cash, providing a runway into 2027.
Key Highlights
- PM577a (Wilson disease) received US IND & NZ CTA clearances for global Phase 1/2 study.
- PM647 (AATD) rights affirmed via arbitration; IND/CTA submission expected 3Q 2026.
- PM359 (CGD) granted FDA RMAT designation; BLA submission targeted 1H 2027.
- Q2 2026 Net Loss was $42.1 million, down from $52.6 million in Q2 2025.
- Q2 2026 R&D expenses decreased to $33.4 million from $41.4 million YoY.
- Cash, cash equivalents, and investments totaled $108.8 million as of June 30, 2026.
- Company expects cash runway to extend into 2027.
Price Impact
More from PRME